Newsletter Tool

Today’s Big News

Sep 18, 2023

BioNTech secures $90M from CEPI to partner on mpox vaccine as it enters clinic

Blackstone's $250M bet beats Xarelto in bleeding trial, making case for Anthos' ex-Novartis asset

Nobel laureate Carolyn Bertozzi joins Acepodia as biotech aims to transform cancer cell therapy

'Quantum therapeutic' triggers glioblastoma cells to self-destruct

Fierce Biotech M&A Tracker 2023: Atriva, Biocure ink reverse takeover; Zevra adds on Acer for $91M

Featured

BioNTech secures $90M from CEPI to partner on mpox vaccine as it enters clinic

By Max Bayer

BioNTech has partnered up with pandemic prevention organization CEPI to the tune of $90 million to help advance a couple of phase 1 stage mpox vaccines. The funding is part of CEPI's latest 100 Days Mission to help stymie future outbreaks.

19-21

Sep

Join us: Digital Pharma East Virtual Event

Virtual Event

Blackstone's $250M bet beats Xarelto in bleeding trial, making case for Anthos' ex-Novartis asset

By Nick Paul Taylor

Blackstone Life Sciences’ $250 million bet on an ex-Novartis drug candidate has racked up another phase 2 win. The data show Anthos Therapeutics’ abelacimab significantly cut bleeding compared to Bayer and Johnson & Johnson’s Xarelto, adding to evidence it can treat thrombosis without affecting hemostasis.

Nobel laureate Carolyn Bertozzi joins Acepodia as biotech aims to transform cancer cell therapy

By Gabrielle Masson

Acepodia has snagged Nobel laureate Carolyn Bertozzi, Ph.D., to serve as chief scientific adviser as the biotech works to transform the cell therapy space for patients with solid tumors and hematologic cancers.

'Quantum therapeutic' triggers glioblastoma cells to self-destruct

By Helen Floersh

In a development fit for a Marvel movie, researchers from the U.K.'s University of Nottingham claim to have developed what they describe as the first “quantum therapeutic”—electrically-charged gold nanoparticles that trigger glioblastoma cells to kill themselves while leaving healthy cells intact.

Fierce Biotech M&A Tracker 2023: Atriva, Biocure ink reverse takeover; Zevra adds on Acer for $91M

By Annalee Armstrong,Max Bayer,Gabrielle Masson

Fierce Biotech's M&A Tracker, your one-stop shop for dealmaking in the biopharma universe.

Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data near

By Max Bayer

Lyndra Therapeutics is laying off staff two months after a CEO swap and as interim data from a pivotal trial for a schizophrenia drug nears. The company's lead asset is a long-acting, oral version of Johnson & Johnson's Uzedy.

Motif Neurotech successfully implants pea-sized 'brain pacemaker' for depression

By Andrea Park

The DOT device measures only about one centimeter across. It doesn’t connect to any leads nor does it contain a battery.

In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use

By Angus Liu

For the JAK inhibitor momelotinib, which GSK obtained in its $1.9 billion acquisition of Sierra Oncology, the three-month extension of the FDA's review turned out to be worth the wait.

Fierce Healthcare's most influential minority executives in healthcare for 2023

By Heather Landi,Susan Kreimer,Annie Burky

We are honoring leaders who have made a measurable impact on healthcare in the past year and have a demonstrated track record in paving the way forward for others. These leaders have shown examples of innovation, passion and ingenuity.

Fierce podcasts